• Title: Javelin Pharmaceuticals Corporate Overview at BioCentury NewsMakers Conference
• Artist: Zangani Investor Community(TM)
• Year: 2007
• Length: 26:29 minutes (6.07 MB)
• Format: Mono 22kHz 32Kbps (CBR)

Javelin Pharmaceuticals CEO, Dr. Daniel B. Carr, provided a corporate overview at the recent BioCentury NewsMakers Conference in New York. Dr. Carr provided updates on the recent progress of Dyloject™ and PMI-150 (intranasal ketamine), two of Javelin's late stage pain care product candidates.

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market.